Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472405 | 0.83 | KIF11 (0.42) | KIF11MEN1LMNATHRBBLM | |
| SCHEMBL31306389 | 0.78 | TDP1 (0.47) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL31306390 | 0.78 | TDP1 (0.47) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL1806887 | 0.78 | TDP1 (0.47) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL6903174 | 0.74 | PTGS1 (0.32) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL22620691 | 0.74 | KDM4E (0.41) | KIF11ERN1ALDH1A1 | |
| SCHEMBL16880572 | 0.74 | — | — | |
| SCHEMBL22620679 | 0.71 | LMNA (0.50) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL9340566 | 0.71 | KIF11 (0.42) | KIF11MEN1LMNATHRBBLM | |
| SCHEMBL154414 | 0.70 | ALDH1A1 (0.44) | MEN1LMNATHRBBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | SHBG, CYP19A1, CYP17A1 | KIF11 1947/4885MEN1 389/4885LMNA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.